Ozturk, Banu TurgutKerimoglu, HurkanAdam, MehmetGunduz, KemalOkudan, Suleyman2020-03-262020-03-2620111056-87271873-460Xhttps://dx.doi.org/10.1016/j.jdiacomp.2010.09.006https://hdl.handle.net/20.500.12395/26525Purpose: To evaluate the effect of glucose regulation on intravitreal ranibizumab injection for clinically significant diabetic macular edema (DME). Methods: This retrospective study enrolled 65 eyes of 65 patients with persistent DME treated with intravitreal ranibizumab injection. The main outcome measures were the change in best corrected visual acuity (BCVA), the central subfield macular thickness (CSMT) recorded with optical coherence tomography (OCT), and its correlation with the serum hemoglobin A(1c) values (HbA(1c)). Results: The study included 24 (36.9%) female and 41(63.1%) male patients with a mean age of 58.90 +/- 9.45 years. The mean HbA(1c) of the enrolled patients was 8.25 +/- 1.74% (range 5.7-12.7%). The median value of BCVA at baseline examination was 20/80 (52 letters), and the median CSMT was 468 pm (range 255-964 mu m). In the final control after 4-6 weeks following injection, the median value of BCVA increased to 20/50 (59.50 letters) and the median CSMT decreased to 310 pin (range 129-652 mu m). This change in BCVA and macular thickness was found to be significant (P<.001 for both). There was no correlation between BCVA and the change in macular thickness (coefficient=0.04, P=.78). The serum HbA(1c) values were found to be negatively correlated with the change in CSMT (coefficient=-0.50, P<.001). Conclusions: The results of intravitreal ranibizumab injection for DME demonstrated a beneficial effect on visual acuity and a decrease in CSMT which is inversely correlated with the serum HbA(1c), level. (C) 2011 Elsevier Inc. All rights reserved.en10.1016/j.jdiacomp.2010.09.006info:eu-repo/semantics/closedAccessRanibizumabDiabetic macular edemaGlucose regulationMacular thicknessArticle25529830221075650Q2WOS:000295193900004Q3